OakChart

MoonLake Immunotherapeutics

MLTXHealthcare·Biotechnology·Switzerland·Small·NASD·Nov 11 • 7:44 AM ET

12.62+0.06 (0.45%)
2026-11-11 14:52 CET
Market cap
1,068.94 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-273.48 USD m
Free cash flow, TTM
-244.04 USD m
EPS diluted, TTM
-3.67
P/E
-
Compare

Price

MLTX against its 20, 50 and 200-day averages
2050200beatmiss
10.0015.0020.003.1M6.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MLTXclose 12.6220-day 11.5050-day 11.96200-day 16.2912.62

45.8% under 23.29 on 22 Jun 2026. Last 15 sessions, 25.2% high to low

Profile

MLTX
52-week range, 23% of the way up
9.4623.29

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Employees130
IPOOct 20, 2020
Beta1.12
ATR, 14d0.75
Rel volume0.00
Short float7.29%
Insider own11.74%
Inst own82.11%

Snapshot

6 groups

Valuation

Index-
Market Cap1.07B
Enterprise Value676.93M
Income-273.48M
Sales0.00M
Book/sh4.48
Cash/sh5.86
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees130
IPOOct 20, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.81
P/C2.15
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.13
Current Ratio9.13
Debt/Eq0.27
LT Debt/Eq0.26
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.67
EPS next Y-3.55
EPS next Q-0.86
EPS this Y-1.02%
EPS next Y0.46%
EPS next 5Y7.76%
EPS past 3/5Y-27.48% -256.78%
Sales past 3/5Y- -
EPS Y/Y TTM-10.20%
Sales Y/Y TTM-
EPS Q/Q15.34%
Sales Q/Q-
EarningsNov 04 BMO
EPS/Sales Surpr.-11.70% -

Ownership

Insider Own11.74%
Insider Trans-4.62%
Inst Own82.11%
Inst Trans14.16%
ROA-57.27%
ROE-81.57%
ROIC-56.71%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA209.72%
SMA505.49%
SMA200-22.55%
Trades-

Technical

Shs Outstand85.11M
Shs Float75.12M
Short Float7.29%
Short Ratio3.28
Short Interest5.47M
52W High23.29 -45.83%
52W Low9.46 33.37%
Volatility8.02% 7.30%
ATR (14)0.75
RSI (14)57.57
Beta1.12
Rel Volume0.00
Avg Volume1.67M
Volume280

Performance

Perf Week9.14%
Perf Month21.20%
Perf Quarter-23.54%
Perf Half Y-31.47%
Perf YTD-4.27%
Perf Year7.38%
Perf 3Y-66.49%
Perf 5Y25.54%
Perf 10Y-
Recom1.75
Target Price32.00
Prev Close12.56
Price12.62
Change %0.45%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 06, 2026InitiatedCChardan Capital MarketsBuy$57+351.8%
Mar 23, 2026UpgradeWWolfe ResearchUnderperform → Outperform$24+90.2%
Mar 19, 2026UpgradeRRothschild & Co RedburnNeutral → Buy$40+217.0%
Jan 15, 2026DowngradeGGoldmanNeutral → Sell$10-20.7%
Jan 09, 2026UpgradeBBTIG ResearchNeutral → Buy$24+90.2%
Nov 03, 2025UpgradeHH.C. WainwrightNeutral → Buy$30+137.8%
Oct 02, 2025DowngradeHH.C. WainwrightBuy → Neutral
Oct 01, 2025DowngradeGGoldmanBuy → Neutral$7-44.5%
Sep 30, 2025DowngradeWWolfe ResearchOutperform → Underperform$2-84.1%
Sep 30, 2025DowngradeCCitigroupBuy → Neutral$5-60.4%

Peers

Mkt cap
TickerCompanyMkt cap
AVTXAvalo Therapeutics Inc415.74M
INCYIncyte Corp23.64B
ALMSAlumis Inc862.38M
ORKAOruka Therapeutics Inc7.40B
PTGXProtagonist Therapeutics Inc8.81B
KYMRKymera Therapeutics Inc11.67B
NVSNovartis AG ADR292.72B
ARQTArcutis Biotherapeutics Inc3.48B
EVMNEvommune Inc287.07M
ABBVAbbvie Inc513.21B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Reich KristianChief Scientific OfficerJul 27 '26Sale20.001,10022,0002,711,198Jul 29 04:10 PM
Reich KristianChief Scientific OfficerJul 21 '26Sale20.0250,0001,001,0002,714,746Jul 23 04:05 PM
Reich KristianChief Scientific OfficerJul 22 '26Sale20.002,44848,9602,712,298Jul 23 04:05 PM
Reich KristianChief Scientific OfficerJul 20 '26Sale20.0943,700877,9332,764,746Jul 21 06:13 PM
Reich KristianChief Scientific OfficerJul 15 '26Sale20.0116,105322,2612,808,446Jul 20 06:07 AM
Reich KristianOfficerJul 15 '26Proposed Sale19.44150,0002,916,000Jul 15 04:46 PM
Santos da Silva JorgeChief Executive OfficerJul 10 '26Sale20.0268,2891,367,1462,774,893Jul 13 04:10 PM
Santos da Silva JorgeChief Executive OfficerJul 09 '26Sale20.0133,936679,0592,843,182Jul 13 04:10 PM
Santos da Silva JorgeChief Executive OfficerJul 01 '26Sale20.0347,775956,9332,877,118Jul 02 04:10 PM
Santos da Silva JorgeOfficerJun 30 '26Proposed Sale20.03150,0003,004,500Jun 30 05:15 PM
Bodenstedt MatthiasChief Financial OfficerJun 22 '26Sale22.0439,120862,2051,115,435Jun 23 04:01 PM
Bodenstedt MatthiasChief Financial OfficerJun 17 '26Sale19.6815,082296,8141,157,349Jun 18 06:45 PM
Bodenstedt MatthiasChief Financial OfficerJun 18 '26Sale19.602,79454,7621,154,555Jun 18 06:45 PM
Reich KristianChief Scientific OfficerJun 17 '26Sale19.4350,000971,5002,824,551Jun 17 06:15 PM

Held by

AUM
TickerCompanyAUM
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.64B
VHTVanguard Health Care ETFAUM: 21.40B
ESMLiShares ESG Aware MSCI USA Small-Cap ETFAUM: 2.78B
TMEDT. Rowe Price Health Care ETFAUM: 38.72M
NUSCNuveen ESG Small-Cap ETFAUM: 1.31B
GWXState Street SPDR S&P International Small Cap ETFAUM: 897.36M
OPTZOptimize Strategy Index ETFAUM: 257.09M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.41B
FHLCFidelity MSCI Health Care Index ETFAUM: 4.10B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.57M

News

latest 14 of 206
  • MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
  • MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near (Stocktwits) -5.08%
  • MoonLakes Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial Retail Shrugs Off Premarket Slide, Says Pipeline Is Intact (Stocktwits) -5.09%
  • MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data (Stocktwits) -5.64%
  • Loading…
  • SLS Vs MLTX: Retail Traders Race To Pick Mercks Next Biotech Buyout As Keytrudas $31.7B Patent Cliff Nears (Stocktwits)
  • MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data A Look At The Latest Development (Stocktwits) -5.75%
  • MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering (GlobeNewswire)
  • MLTX Stock Clocks Best Day In Over 6 Months Whats Driving The Investor Optimism? (Stocktwits) +15.36%
  • MoonLake Immunotherapeutics Announces Proposed Public Offering (GlobeNewswire)
  • Why Is MLTX Stock Rallying Nearly 20% Overnight? (Stocktwits)
  • MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 (GlobeNewswire)
  • MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts (Stocktwits)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.930-0.833-0.9300.000.0013
2026Q22026-08-10-0.840-0.918-0.8360.000.0013
2026Q12026-05-10-0.980-0.892-0.9780.000.0012
2025Q42026-02-22-0.932-0.964-0.9210.000.0013
2025Q32025-11-05-1.100-0.879-1.1000.000.0016
2025Q22025-08-05-0.870-0.740-0.8730.000.0015
2025Q12025-05-12-0.630-0.754-0.6320.000.0014
2024Q42025-02-26-0.720-0.620-0.7230.000.0013
2024Q32024-11-07-0.560-0.436-0.5630.000.0015
2024Q22024-08-07-0.390-0.277-0.3860.000.0013
2024Q12024-05-07-0.220-0.193-0.2180.000.0011
2023Q42024-02-29-0.120-0.230-0.1240.000.0013
2023Q32023-11-14-0.180-0.230-0.1760.000.0011
2023Q22023-08-10-0.230-0.266-0.2320.000.0010
2023Q12023-05-12-0.230-0.306-0.2310.000.008
2022Q42023-03-20-0.310-0.328-0.3050.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-1.700-1.476-1.7020.000.00
2023FY-0.730-0.895-0.7330.000.00
2024FY-1.890-1.788-1.8920.000.00
2025FY-3.538-3.566-3.5580.000.00
2026FY--3.566--0.00
2027FY--3.550--18.24
2028FY--2.770--106
2029FY--0.552--455.29
2030FY-2.267--852.34

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-077000.000.000.00
2026Q4S2026-11-048000.000.000.00
2026Q4S2026-08-138000.000.000.00
2026Q4S2026-08-109000.000.000.00
2026Q4S2026-07-309000.000.000.00
2026Q4S2026-05-118000.000.000.00
2026Q4S2026-03-196000.000.000.00
2026Q4S2026-02-275000.000.000.00
2026Q4S2026-02-254000.000.000.00
2026Q4S2026-02-233000.000.000.00
2026Q4S2026-02-053000.000.000.00
2026Q4S2025-12-102000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00

Estimate history

EPS, annual-0.006-6.842-1.702-0.733-1.892-3.526-3.667
Period202020212022202320242025TTM
EPS, quarterly-0.563-0.723-0.632-0.873-1.1-0.921-0.978-0.836-0.932
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual14.80510.21838.97860.46663.07771.37485.107
Period202020212022202320242025MRQ
Shares, quarterly63.04663.07763.47463.47463.70571.37472.13483.60785.107
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.402.621.380.010.010.000.00
Gross Profit-3.40-2.62-1.38-0.01-0.01-0.000.00
Selling, General and Administrative Excl. Other273.36242.22141.7154.1165.0553.570.11
Research and Development226.22200.25111.3931.7942.0435.52-
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-276.75-244.83-143.09-54.12-65.06-53.58-0.11
Interest Expense9.557.250.000.00-0.00-
Unusual Expense0.000.000.000.000.000.000.00
Net Income Before Taxes-272.48-229.71-120.96-43.98-64.47-53.64-0.09
Income Taxes1.590.610.280.090.040.000.00
Consolidated Net Income-274.07-230.32-121.24-44.08-64.51-53.64-0.09
Net Income From Continuing Operations-273.48-227.32-118.94-36.01-49.97-53.64-0.09
Net Income-273.48-227.32-118.94-36.01-49.97-53.64-0.09
EPS (Recurring)-3.20-3.53-1.89-0.73-1.70-6.84-0.01
EPS (Basic, Before Extraordinaries)-3.67-3.53-1.89-0.73-1.70-6.84-0.01
EPS (Diluted)-3.67-3.53-1.89-0.73-1.70-6.84-0.01
EBITDA-273.36-242.22-141.71-54.11-65.05-53.57-0.11
Non-Operating Income (Expense)13.8222.3722.1310.140.59-0.060.01
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense17.6510.195.755.617.636.61-
Shares Outstanding85.1171.3763.0860.4738.9810.2214.80
Market Capitalization1,068.941,068.943,414.913,619.81409.26146.42168.33

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.910.900.840.750.740.740.381.30
Gross Profit-0.91-0.90-0.84-0.75-0.74-0.74-0.38-1.30
Selling, General and Administrative Excl. Other78.9560.7669.1864.4770.6959.9647.1148.28
Research and Development67.9749.3353.6755.2659.8949.0236.0839.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-79.85-61.66-70.02-65.22-71.43-60.70-47.48-49.58
Interest Expense2.652.632.271.993.202.040.020.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-78.91-61.72-69.08-62.77-70.58-55.96-40.41-46.35
Income Taxes0.630.090.620.250.120.100.150.04
Consolidated Net Income-79.55-61.80-69.71-63.02-70.69-56.05-40.56-46.40
Net Income From Continuing Operations-79.55-61.80-69.71-62.43-69.73-55.22-39.94-45.60
Net Income-79.55-61.80-69.71-62.43-69.73-55.22-39.94-45.60
EPS (Recurring)-0.93-0.84-0.98-0.92-1.10-0.87-0.63-0.72
EPS (Basic, Before Extraordinaries)-0.93-0.84-0.98-0.92-1.10-0.87-0.63-0.72
EPS (Diluted)-0.93-0.84-0.98-0.92-1.10-0.87-0.63-0.72
EBITDA-78.95-60.76-69.18-64.47-70.69-59.96-47.11-48.28
Non-Operating Income (Expense)3.592.583.214.444.056.787.103.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.252.0110.552.842.932.611.811.53
Shares Outstanding85.1183.6172.1371.3763.7063.4763.4763.08
Market Capitalization1,068.941,433.291,337.01933.77455.312,995.992,472.463,414.91

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments393.97448.03511.0172.118.041.34
Short Term Receivables4.872.841.060.220.150.00
Inventories0.000.000.000.000.000.00
Other Current Assets22.8623.422.104.181.450.28
Total Current Assets421.69474.29514.1776.519.641.62
Net Property, Plant & Equipment2.143.643.950.330.050.00
Total Investments and Advances0.000.000.000.000.00115.01
Intangible Assets-0.000.000.000.000.00
Other Assets0.600.008.420.000.000.00
Total Assets424.43477.93526.5476.849.68116.63
Short Term Debt Incl. Current Port. of LT Debt1.231.371.200.1515.000.06
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable1.090.640.370.110.06-
Other Current Liabilities43.1520.458.407.406.020.07
Total Current Liabilities45.4822.469.977.6721.090.13
Long Term Debt74.471.462.500.130.000.00
Provision for Risks Charges0.000.620.580.280.240.00
Other Liabilities0.000.000.000.000.004.03
Total Liabilities119.9524.5413.058.0821.334.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.070.00
Common Equity304.48446.83495.6848.90-11.72112.48
Total Shareholders Equity304.48446.83495.6848.90-11.65112.48
Accumulated Minority Interest0.006.5717.8219.870.000.00
Total Equity304.48453.39513.4968.77-11.65112.48
Total Liabilities & Stockholders Equity424.43477.93526.5476.849.68116.63
Book Value Per Share4.277.088.201.25-1.157.60
Tangible Book Value Per Share4.277.088.201.25-1.157.60
Full-Time Employees130100502022
Price to Book Ratio2.806.997.617.011.361.50
Return on Assets-50.38-23.68-11.94-51.87-84.94-
Return on Equity-60.51-25.24-13.22-63.73-106.39-
Return on Invested Capital-59.99-26.53-7.23-101.93--0.08
Quick Ratio9.2721.1151.599.980.4612.93
Current Ratio9.2721.1151.599.980.4612.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-274.07-230.32-121.24-44.08-64.51-53.64-0.09
Depreciation3.402.621.380.010.010.00-
Other Funds (Non Cash)23.4211.827.067.5110.0313.98-0.01
Funds from Operations-247.26-215.88-112.80-36.56-54.47-39.66-0.10
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital3.2219.88-3.78-6.22-1.434.48-0.22
Cash from Operating Activities-244.04-196.01-116.59-42.78-55.89-35.18-0.32
Capital Expenditures0.00-0.04-0.52-0.28-0.02-0.050.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-88.25203.03-205.08-24.90-32.320.00-115.00
Purchase of Investments-265.27-265.37-350.28-175.73-42.230.00-115.00
Sale Or Maturity of Investments177.01468.40145.20150.839.900.00-
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-88.25202.99-205.60-25.18-32.34-0.05-115.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock341.6772.9752.78482.450.0028.26117.00
Repurchase of Common Pref Stock0.000.00-5E-050.000.00-0.010.00
Sale of Common Pref Stock341.6772.9752.78482.450.0028.27117.00
Proceedsfrom Stock Options340.9472.8852.78482.450.0028.27117.00
Issuance or Reduction of Debt, Net24.4773.020.000.00-15.0015.000.00
Change in Long Term Debt24.4773.020.000.000.000.000.00
Issuance of Long Term Debt24.4773.020.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.500.00-1.47-2.75134.690.00-0.35
Other Financing Activities Uses-1.500.00-1.47-2.750.000.00-0.35
Cash from Financing Activities364.63146.0051.31479.70119.6943.26116.65
Exchange Rate Effect-0.391.110.13-0.080.010.00-
Net Change in Cash31.95154.09-270.74411.6631.478.041.34
Free Cash Flow-244.04-196.04-117.11-43.06-55.91-35.23-0.32
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments498.46537.03357.92393.97380.48425.08
Short Term Receivables8.956.565.764.874.023.41
Inventories0.000.000.000.000.000.00
Other Current Assets25.9326.4532.9622.8626.7126.99
Total Current Assets533.34570.04396.64421.69411.21455.48
Net Property, Plant & Equipment2.162.562.392.142.532.92
Total Investments and Advances0.000.000.000.000.000.00
Other Assets5.221.341.340.600.591.70
Total Assets540.72573.95400.37424.43414.33460.10
Short Term Debt Incl. Current Port. of LT Debt0.961.250.921.231.501.55
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable0.682.351.401.091.010.84
Other Current Liabilities56.7941.8043.8043.1545.8524.98
Total Current Liabilities58.4345.3946.1145.4848.3727.36
Long Term Debt100.66100.2999.8874.4774.2374.22
Provision for Risks Charges0.000.070.350.000.550.57
Other Liabilities0.000.000.000.000.000.00
Total Liabilities159.09145.75146.35119.95123.14102.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity381.63428.19254.02304.48288.91353.73
Total Shareholders Equity381.63428.19254.02304.48288.91353.73
Accumulated Minority Interest0.000.000.000.002.294.21
Total Equity381.63428.19254.02304.48291.19357.94
Total Liabilities & Stockholders Equity540.72573.95400.37424.43414.33460.10
Book Value Per Share4.485.123.524.274.545.57
Tangible Book Value Per Share4.485.123.524.274.545.57
Full-Time Employees---130--
Price to Book Ratio2.805.534.372.911.297.35
Return on Assets-57.27-51.00-56.40-50.38-45.14-35.06
Return on Equity-81.57-67.44-77.72-60.51-54.18-40.29
Return on Invested Capital-16.49-11.69-19.70-16.47-19.20-12.90
Quick Ratio9.1312.568.609.278.5016.65
Current Ratio9.1312.568.609.278.5016.65

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-79.54-61.81-69.71-63.02-70.69-56.05
Depreciation0.910.900.840.750.740.74
Other Funds (Non Cash)3.592.5713.793.473.971.97
Funds from Operations-75.05-58.34-55.07-58.80-65.97-53.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.652.78-11.210.0121.43-1.19
Cash from Operating Activities-63.40-55.56-66.29-58.79-44.54-54.53
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-58.760.320.10-29.9188.4088.25
Purchase of Investments-88.29-58.75-59.07-59.170.00-117.66
Sale Or Maturity of Investments29.5259.0759.1729.2688.40205.91
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-58.760.320.10-29.9188.4088.25
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock28.47234.626.1872.390.480.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock28.47234.626.1872.390.480.00
Proceedsfrom Stock Options28.47234.076.0172.390.380.00
Issuance or Reduction of Debt, Net0.000.0024.470.000.000.00
Change in Long Term Debt0.000.0024.470.000.000.00
Issuance of Long Term Debt0.000.0024.470.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.500.000.000.000.000.00
Other Financing Activities Uses-1.500.000.000.000.000.00
Cash from Financing Activities26.97234.6230.6472.390.480.00
Exchange Rate Effect-0.020.03-0.480.09-0.281.39
Net Change in Cash-95.22179.41-36.03-16.2244.0535.12
Free Cash Flow-63.40-55.56-66.29-58.79-44.54-54.53

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.29%5.5M75.1M1.68M
2026-10-1510.43%7.8M75.1M1.50M
2026-09-3010.71%8.0M75.1M1.38M
2026-09-1511.91%8.9M75.1M1.37M
2026-08-319.51%7.1M75.1M1.24M
2026-08-149.09%6.8M75.0M1.20M
2026-07-317.85%5.7M72.9M1.12M
2026-07-158.86%6.3M71.5M1.09M
2026-06-3010.31%6.6M63.6M1.17M
2026-06-158.38%5.3M63.5M991.54K
2026-05-298.81%5.6M63.2M1.00M
2026-05-158.65%5.5M63.2M1.15M
2026-04-309.84%6.3M64.3M1.14M
2026-04-1510.58%6.7M62.9M1.27M
2026-03-3112.33%7.8M62.9M1.97M
2026-03-1311.63%7.3M62.9M2.01M
2026-02-2711.32%7.0M62.1M2.20M
2026-02-1311.70%7.3M62.1M2.24M
2026-01-3011.12%7.0M63.1M2.46M
2026-01-1511.38%7.2M63.1M2.69M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call3.008.6010.6014.6910.8541.000.000.988-0.0150.001
call5.006.608.600.007.1420.000.000.982-0.0150.001
call6.005.607.600.005.9720.000.000.978-0.0150.001
call7.004.606.600.005.0180.000.000.972-0.0140.001
call8.003.605.600.004.2040.000.000.966-0.0140.002
call9.002.304.500.003.3080.000.000.827-0.0780.005
call10.001.303.202.502.1831,5120.000.787-0.0710.006
call11.000.052.400.631.9352,0350.000.729-0.0620.007
call12.000.851.451.001.4232530.000.623-0.0600.008
call13.000.450.800.651.1961,2553030.479-0.0540.008
call14.000.100.450.321.1604021210.320-0.0440.007
call15.000.050.250.151.1622941410.203-0.0350.006
call16.000.000.900.101.40866.0010.000.177-0.0390.005
call17.000.001.700.151.6252480.000.159-0.0420.005
call18.000.000.700.081.8211410.000.147-0.0440.005
call19.000.001.700.282.10635.000.000.154-0.0520.005
call20.000.001.700.102.1654790.000.129-0.0480.004
call21.000.000.950.502.43110.000.000.139-0.0570.005
call22.000.000.950.102.57637.000.000.133-0.0580.004
call23.000.001.702.372.71332.000.000.128-0.0600.004
call24.000.000.700.302.8412,0440.000.124-0.0610.004
call25.000.001.700.152.8361,4530.000.107-0.0550.004
call26.000.000.650.153.0763.000.000.118-0.0640.004
call27.000.001.702.153.1851.000.000.115-0.0650.004
call28.000.001.701.373.2884.000.000.112-0.0660.004
call29.000.001.700.353.38761.000.000.110-0.0670.004
call30.000.001.700.113.3458900.000.095-0.0590.003
call31.000.001.700.253.5717.000.000.106-0.0690.004
call32.000.001.700.253.65716.000.000.105-0.0700.004
call33.000.000.700.003.7400.000.000.103-0.0700.004
call34.000.001.701.103.8206.000.000.102-0.0710.004
call35.000.001.701.003.89726.000.000.100-0.0720.004
put3.000.001.700.004.6200.000.00-0.012-0.0150.001
put5.000.001.700.153.0531.000.00-0.018-0.0140.001
put6.000.001.700.002.5030.000.00-0.022-0.0140.001
put7.000.001.100.052.03810.000.00-0.028-0.0130.001
put8.000.000.050.242.62586.000.00-0.110-0.0500.004
put9.000.001.650.052.8841950.00-0.173-0.0770.005
put10.000.001.700.102.3021,0000.00-0.213-0.0700.006
put11.000.000.700.211.7496550.00-0.271-0.0600.007
put12.000.150.950.401.5161,1610.00-0.377-0.0590.008
put13.000.551.451.831.46952.000.00-0.521-0.0530.008
put14.001.352.653.072.14371.000.00-0.680-0.0420.007
put15.002.302.852.831.4404931,001-0.797-0.0330.006
put16.002.304.302.252.35133.000.00-0.823-0.0370.005
put17.003.405.402.852.74831.000.00-0.841-0.0400.005
put18.004.406.405.502.98624.000.00-0.853-0.0420.005
put19.005.407.407.033.20216.000.00-0.863-0.0440.005
put20.006.408.404.703.40016.000.00-0.871-0.0460.004
put21.007.509.405.603.58382.000.00-0.877-0.0470.004
put22.008.5010.406.513.75399.000.00-0.882-0.0490.004
put23.009.5011.406.903.91314.000.00-0.886-0.0500.004
put24.0010.0013.000.004.8960.000.00-0.890-0.0510.004
put25.0011.0014.008.805.0430.000.00-0.893-0.0520.004
put26.0012.0015.009.405.1820.000.00-0.896-0.0530.004
put27.0013.0016.000.005.3140.000.00-0.899-0.0540.004
put28.0014.0017.000.005.4390.000.00-0.901-0.0550.004
put29.0015.0018.000.005.5580.000.00-0.903-0.0550.004
put30.0016.0019.000.005.6710.000.00-0.905-0.0560.003
put31.0017.0020.000.005.7800.000.00-0.907-0.0570.003
put32.0018.0021.000.005.8840.000.00-0.908-0.0570.003
put33.0019.0022.000.005.9840.000.00-0.910-0.0580.003
put34.0020.0023.000.006.0800.000.00-0.911-0.0590.003
put35.0021.0024.000.006.1720.000.00-0.912-0.0590.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-10S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-15144Filing for proposed sale of securities under Rule 144.SEC
2026-07-158-KCurrent report2026-07-14SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29SCHEDULE 13D/ASEC
2026-06-258-KCurrent report2026-06-23SEC
2026-06-24424B5SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-22424B5SEC
2026-06-228-KCurrent report2026-06-21SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07005.28M8
2026-06004.06M6
2026-0500273.33K1
2026-04004.46M5
2026-030062.96M1
2026-020000
2026-010000
2025-12005.99M4
2025-110000

Institutional holders

Manager% owned
BVF INC/IL21.74%
Deep Track Capital, LP9.51%
T. Rowe Price Investment Management, Inc.5.81%
D. E. Shaw & Co., Inc.4.57%
Jupiter Topco LLC4.19%
Logos Global Management LP3.63%
Weiss Asset Management LP3.51%
CITADEL ADVISORS LLC2.68%
TWO SIGMA INVESTMENTS, LP2.33%
MPM BioImpact LLC2.18%

Funds

Fund% owned
T. Rowe Price Capital Appreciation Fund2.19%
T. Rowe Price Small-Cap Value Fund, Inc.1.25%
T. Rowe Price Health Sciences Fund, Inc.1.08%
JNL/T. Rowe Price Capital Appreciation Fund 0.48%
T. Rowe Price Capital Appreciation Equity ETF0.23%
VY(R) T. ROWE PRICE CAPITAL APPRECIATION PORTFOLIO0.22%
BlackRock Health Sciences Opportunities Portfolio0.19%
Select Biotechnology Portfolio0.17%
VANGUARD HEALTH CARE INDEX FUND0.15%
NORTH SQUARE DYNAMIC SMALL CAP FUND0.15%

OakChart. MLTX. Cached 15 minutes.